

Structural basis of Gabija anti-phage defense and viral immune evasion

Sadie P. Antine^{1,2}, Alex G. Johnson^{1,2}, Sarah E. Mooney^{1,2}, Azita Leavitt³, Megan L. Mayer⁴, Erez Yirmiya³, Gil Amitai³, Rotem Sorek³, Philip J. Kranzusch^{1,2,5*}

¹ Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA

² Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

³ Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel

⁴ Harvard Center for Cryo-Electron Microscopy, Harvard Medical School, Boston, MA 02115, USA

⁵ Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA 02115, USA

*Correspondence: philip_kranzusch@dfci.harvard.edu

1 **Bacteria encode hundreds of diverse defense systems that protect from viral infection and**
2 **inhibit phage propagation^{1–5}. Gabija is one of the most prevalent anti-phage defense**
3 **systems, occurring in >15% of all sequenced bacterial and archaeal genomes^{1,6,7}, but the**
4 **molecular basis of how Gabija defends cells from viral infection remains poorly**
5 **understood. Here we use X-ray crystallography and cryo-EM to define how Gabija proteins**
6 **assemble into an ~500 kDa supramolecular complex that degrades phage DNA. Gabija**
7 **protein A (GajA) is a DNA endonuclease that tetramerizes to form the core of the anti-phage**
8 **defense complex. Two sets of Gabija protein B (GajB) dimers dock at opposite sides of the**
9 **complex and create a 4:4 GajAB assembly that is essential for phage resistance *in vivo*.**
10 **We show that a phage-encoded protein Gabija anti-defense 1 (Gad1) directly binds the**
11 **Gabija GajAB complex and inactivates defense. A cryo-EM structure of the virally inhibited**
12 **state reveals that Gad1 forms an octameric web that encases the GajAB complex and**
13 **inhibits DNA recognition and cleavage. Our results reveal the structural basis of assembly**
14 **of the Gabija anti-phage defense complex and define a unique mechanism of viral immune**
15 **evasion.**

16 Bacterial Gabija defense operons encode the proteins GajA and GajB that together protect
17 cells against diverse phages¹. To define the structural basis of Gabija anti-phage defense, we co-
18 expressed *Bacillus cereus* VD045 GajA and GajB and determined a 3.0 Å X-ray crystal structure
19 of the protein complex (Fig. 1a,b, Extended Data Fig. 1a,b, and Extended Data Table 1). The
20 structure of the GajAB complex reveals an intricate 4:4 assembly with a tetrameric core of GajA
21 subunits braced on either end by dimers of GajB (Fig. 1b). Focusing first on individual Gabja
22 protein subunits, GajA contains an N-terminal ATPase domain that is divided into two halves by
23 insertion of a protein dimerization interface (discussed further below) (Fig. 1c). The GajA ATPase
24 domain consists of an eleven-stranded β-sheet $\beta 1^{ABC}$, 2^{ABC} , $4–6^{ABC}$ and $\beta 3^{ABC}$, $7–11^{ABC}$ that folds
25 around the central $\alpha 1^{ABC}$ helix (Fig. 1c, Extended Data Fig. 2). Sequence analysis of diverse GajA
26 homologs demonstrates that the GajA ATPase domain contains a highly conserved ATP-binding

27 site shared with canonical ABC ATPase proteins (Extended Data Fig. 2)⁸. The GajA C-terminus
28 contains a four-stranded parallel β -sheet β 1–4^T surrounded by three α -helices α 3^T, α 4^T, and α 12^T
29 that form a Toprim (topoisomerase-primase) domain associated with proteins that catalyze
30 double-stranded DNA breaks (Fig. 1c, Extended Data Fig. 2)^{9,10}. Consistent with a role in dsDNA
31 cleavage, the structure of GajA confirms previous predictions of overall shared homology between
32 GajA and a class of DNA endonucleases named OLD (overcoming lysogenization defect)
33 nucleases^{11,12}. Discovered initially as an *E. coli* phage P2 protein responsible for cell toxicity in
34 *recB*, *recC* mutant cells^{13–15}, OLD nucleases occur in diverse bacterial genomes as either single
35 proteins (Class 1) or associated with partner UvrD/PcrA/Rep-like helicase proteins (Class 2), but
36 the specific function of most OLD nuclease proteins is unknown^{11,12}. GajA is a Class 2 OLD
37 nuclease with the Toprim domain containing a complete active site composed of DxD after β 3^T
38 (D432 and D434), an invariant glutamate following β 2^T (E379), and an invariant glycine between
39 α 1^T and β 1^T (G409) similar to the active site of *Burkholderia pseudomallei* (*BpOLD*) previously
40 demonstrated to be essential for a two-metal-dependent mechanism of DNA cleavage (Fig. 1d,
41 Extended Data Fig. 2)¹¹.

42 The structure of GajB reveals a Superfamily 1A DNA helicase domain typically occurring
43 in bacterial DNA repair (Fig. 1a,b)¹⁶. Superfamily 1A helicase proteins like UvrD, Rep, and PcrA
44 translocate along ssDNA in the 3'-5' direction, and are architecturally divided into four
45 subdomains 1A, 1B, 2A, and 2B that reposition relative to each other during helicase function¹⁶.
46 GajB contains all conserved helicase motifs required for ATP hydrolysis and nucleic acid
47 unwinding including a Walker A motif Gx(4)GK-[TT] and a UvrD-like DEXQD-box Walker B motif
48 responsible for NTP hydrolysis (Fig. 1f and Extended Data Fig. 3a)^{16–18}. Activation of Superfamily
49 1A DNA helicase proteins like UvrD and Rep is known to require protein dimerization and rotation
50 of the 2B subdomain^{19–21}. Comparisons with UvrD and Rep demonstrate that GajB protomers in
51 the GajAB complex exhibit partial rotation of the 2B domain relative to 2A-1A-1B consistent with
52 a partially active conformation poised to interact with phage DNA (Fig. 1e and Extended Data

53 Figure 1d).

54

55 **Mechanism and function of Gabija supramolecular complex formation**

56 To define the mechanism of Gabija complex assembly, we analyzed oligomerization
57 interfaces within the GajAB structure. Purification of individual Gabija proteins demonstrates that
58 GajA is alone sufficient to oligomerize into a homo-tetrameric assembly (Extended Data Fig. 1b).
59 GajB migrates as a monomer on size-exclusion chromatography, supporting a stepwise model of
60 GajAB assembly (Fig. 2a and Extended Data Fig. 1b). GajA tetramers form through two highly-
61 conserved oligomerization interfaces (Fig. 2b,c and Extended Data Fig. 2). First, the GajA N-
62 terminal ATPase domain contains an insertion between $\beta7^{ABC}$ and $\beta8^{ABC}$ that consists of four α -
63 helices ($\alpha1-4^D$) that zip-up against a partnering GajA protomer to form a hydrophobic interface
64 along the $\alpha2^D$ helix (Fig. 2b). A similar $\alpha1-4^D$ dimerization interface exists in the structure of the
65 bacterial *T. scotoductus* Class 1 OLD (*TsOLD*) protein demonstrating that this interface is
66 conserved within divergent OLD nucleases (Figs. 1c and 2c)¹². The GajA ATPase domain
67 contains a second oligomerization interface in a loop between $\beta6^{ABC}$ and $\alpha6^{ABC}$ where hydrogen
68 bond contacts between D135 and R139 interlock two GajA dimers to form the tetrameric core
69 assembly (Fig. 2c). Compared to GajA, the GajB–GajB dimerization interface is minimal and
70 consists of a hydrophobic surface in the GajB helicase 1B domain centered at Y119 and I122
71 (Fig. 2d). Major GajA–GajB contacts also occur in the GajB helicase 1B domain where GajA R97
72 in a loop between $\alpha4^{ABC}$ and $\beta5^{ABC}$ forms hydrogen-bond contacts with Q150 in GajB $\alpha7$ along
73 with hydrophobic packing interactions centered at GajB V147 (Fig. 2d and Extended Data Fig.
74 3a). Notably, the GajAB structure demonstrates that the GajB helicase 1A subdomain including
75 the DEXQD-box active-site is positioned adjacent to the GajA ATPase domain suggesting that
76 GajB ATP-hydrolysis and DNA unwinding activity may regulate GajA ATPase domain activation
77 (Fig. 2e). In addition to the major GajAB interface contacts, Gabija supramolecular complex
78 assembly is driven by extensive protomer interactions that result in ~31,000 Å² of surface area

79 buried for the GajA tetramer and ~1,800 Å² of surface area buried for each GajB subunit.

80 We reconstituted Gabija activity *in vitro* and observed that the GajAB complex rapidly
81 cleaves a previously characterized 56 bp dsDNA substrate containing a sequence specific motif
82 derived from phage lambda DNA (Extended Data Fig. 1c)²². GajA and GajB proteins are each
83 essential for phage defense *in vivo*^{1,22}, but we observed *in vitro* that GajA alone is sufficient to
84 cleave target DNA suggesting a specific role for the GajAB complex in substrate recognition or
85 nuclease activation during phage infection (Extended Data Fig. 1c). To confirm these findings, we
86 tested a panel of GajAB interface mutations and measured the impact of substitutions on the
87 ability of Gabija to defend *B. subtilis* cells from phage SPβ infection. Substitutions to the GajA–
88 GajA dimerization interface including I199E, I212E, and K229E resulted in complete loss of phage
89 resistance (Fig. 2f). Likewise, substitutions to the GajA–GajB hetero-oligomerization interface
90 including GajA K94E, R97A and GajB V147E dramatically reduced the ability of Gabija to inhibit
91 phage replication *in vivo*. In contrast, phage resistance was tolerant to mutations in the GajB–
92 GajB interface suggesting that this minimal interaction surface is not strictly essential for anti-
93 phage defense. Together, these results define the structural basis of GajA and GajB interaction
94 and demonstrate that GajAB supramolecular complex formation is critical for Gabija anti-phage
95 defense.

96

97 **Structural basis of viral inhibition of Gabija anti-phage defense**

98 To overcome host immunity, phages encode evasion proteins that specifically inactivate
99 anti-phage defense^{23–28}. Yirmiya, Leavitt, and colleagues report discovery of the first viral inhibitor
100 of Gabija anti-phage defense (Yirmiya and Leavitt et al 2023 Submitted Manuscript), and we
101 reasoned that defining the mechanism of immune evasion would provide further insight into
102 Gabija complex function. Gabija anti-defense 1 (Gad1) is a *Bacillus* phage Phi3T protein that is
103 atypically large (35 kDa) compared to other characterized phage immune evasion proteins
104 (Extended Data Fig. 4). Protein interaction analysis demonstrated that Gad1 binds directly to

105 GajAB (Extended Data Fig. 5a,b), and we used cryo-EM to determine a 2.7 Å structure of the
106 GajAB–Gad1 co-complex assembly (Fig. 3a,b, Extended Data Figs. 6 and 7a–f, and Extended
107 Data Table 2). The GajAB–Gad1 co-complex structure reveals a striking mechanism of inhibition
108 where Gad1 proteins form an oligomeric web that wraps 360° around the host defense complex.
109 Eight copies of phage Gad1 encircle the GajAB assembly, forming a 4:4:8 GajAB–Gad1 complex
110 that is ~775 kDa in size (Fig. 3b,c). Gad1 primarily recognizes the GajA nuclease core, forming
111 extensive contacts along the surface of the GajA dimerization domain (Fig. 3c,d). Key GajAB–
112 Gad1 contacts include hydrogen-bond interactions from a Gad1 positively-charged loop located
113 between β 6 and β 7 with GajA α 2^D (Fig. 3e and Extended Data Fig. 8) and hydrophobic packing
114 interactions between Gad1 Y190 and F192 with GajA α 2^D (Fig. 3f and Extended Data Fig. 8).
115 Although Gad1 contacts with GajB are limited, both GajA and GajB proteins are necessary for
116 Gad1 interaction, demonstrating that Gad1 specifically targets the fully assembled GajAB
117 complex to inactivate host anti-phage defense (Extended Data Fig. 5c).

118 Gad1 wraps around the GajAB complex using a network of homo-oligomeric interactions
119 and remarkable conformational flexibility. On either side of the GajAB complex, four copies of
120 Gad1 interlock into a tetrameric interface along the primary GajA binding site (Fig. 3d). The Gad1
121 tetrameric interface is formed by hydrogen-bond interactions between the C-termini “shoulder”
122 domain of each Gad1 monomer and a highly conserved set of three cysteine residues C282,
123 C284, and C285 that form disulfide interactions deep within an inter-subunit interface (Fig. 3d,g
124 and Extended Data Fig. 8). The N-termini of each Gad1 monomer forms an “arm” domain that
125 extends out from the shoulder and reaches around the GajA nuclease active site to connect to a
126 partnering Gad1 protomer from the opposite side of the complex. At the end of the Gad1 arm is
127 an N-terminal “fist” domain that allows two partnering Gad1 protomers to interact and complete
128 the octameric web assembly (Fig. 3c,h). Particle heterogeneity limits resolution in this portion of
129 the cryo-EM map, but AlphaFold2 modeling^{29,30} and rigid-body placement of the Gad1 N-terminal
130 fist domain suggests conserved hydrophobic residues around the Gad1 α 1 helix mediate the fist–

131 fist interactions (Fig. 3h and Extended Data Fig. 8). To fully encircle GajAB, Gad1 adopts two
132 distinct structural conformations. Each pair of Gad1 proteins that wrap around and connect at the
133 GajAB complex edge are formed by one Gad1 protomer reaching out from the shoulder with an
134 arm domain extended straight down and one Gad1 protomer reaching out with an arm domain
135 bent ~34° to the left (Fig. 3i and Extended Data Fig. 7h). Sequence analysis of Gad1 proteins
136 from phylogenetically diverse phages demonstrates that the Gad1 N-terminal arm domain is
137 highly variable in length (Extended Data Fig. 8), further supporting that conformational flexibility
138 in this region is critical to inhibit host Gabija defense.

139 To test the importance of individual GajAB–Gad1 interfaces, we next analyzed a series of
140 Gad1 substitution and truncation mutants for the ability to interact with GajAB and inhibit Gabija
141 anti-phage defense. A Gad1 substitution F192R between β4 and β5 at the center of the primary
142 GajA–Gad1 interface disrupted all ability of Gad1 to interact with GajAB *in vitro* and inhibit Gabija
143 anti-phage defense *in vivo* (Fig. 3j and Extended Data Fig. 9a). However, individual mutations
144 throughout the periphery were insufficient to disrupt Gad1 inhibition of Gabija anti-phage defense,
145 demonstrating that the large footprint of Gad1 is tolerant to small perturbations that may enable
146 host resistance. Likewise, mutations to the conserved Gad1 cysteine residues in the tetrameric
147 shoulder interface greatly reduced stability of the GajAB–Gad1 complex formation *in vitro* but
148 exhibited an ~3-fold difference and still permitted Gad1 to block phage defense in *B. subtilis* cells
149 (Fig. 3j and Extended Data Fig. 9a). Finally, in contrast to wildtype Gad1, expression of the Gad1
150 N-terminal fist-arm or C-terminal shoulder domains alone were unable to inhibit Gabija,
151 demonstrating that full wrapping of Gad1 around the GajAB complex is necessary to enable
152 phage evasion of anti-phage defense (Fig. 3j and Extended Data Fig. 9a).

153

154 **Inhibition of Gabija DNA binding and cleavage enables viral evasion**

155 To define the mechanism of Gad1 inhibition of Gabija anti-phage defense, we next
156 modeled interactions between GajAB and target DNA. The GajA Toprim domain is structurally

157 homologous to the *E. coli* protein MutS involved in DNA repair³¹. Superimposing the MutS–DNA
158 structure revealed positively charged patches lining a groove in the GajA Toprim domain that dips
159 into the nuclease active site (Extended Data Fig. 10). Notably, the Gad1 arm domain directly
160 occupies this putative DNA-binding surface supporting a model where the phage protein directly
161 clashes with the path of target dsDNA (Fig. 4a,b). To determine the impact of viral inhibition on
162 GajAB catalytic function we tested the role of Gad1 in individual steps of DNA binding and target
163 DNA cleavage. Gad1 prevented GajAB from binding to target DNA and abolished all nuclease
164 activity *in vitro* (Fig. 4c,d). Mutant Gad1 proteins F192R and C282E were no longer able to inhibit
165 DNA cleavage, agreeing with the complete loss of F192R and reduced ability of C282E mutant
166 proteins to block Gabija defense *in vivo* and form stable GajAB–Gad1 complexes *in vitro*.
167 (Extended Data Fig. 9b). Together, these results demonstrate that phage Gad1 binds and wraps
168 around the GajAB complex to block target DNA degradation and define a complete mechanism
169 for immune evasion of Gabija anti-phage defense (Fig. 4e).

170 Our study defines the structural basis of Gabija supramolecular complex formation and
171 explains how phages block DNA cleavage to defeat this form of host immunity. Similar to
172 supramolecular complexes in CRISPR³², CBASS^{33,34}, and RADAR immunity^{35,36}, the ~500 kDa
173 GajAB complex extends an emerging theme in anti-phage defense where protein subunits
174 assemble into large machines to resist phage infection. These results parallel human innate
175 immunity, where key effectors in inflammasome, Toll-like receptor, RIG-I-like receptor, and cGAS-
176 STING signaling pathways also oligomerize into large assemblies to block viral replication^{37,38}. In
177 contrast to the exceptionally large host defense complexes, phage evasion proteins are typically
178 small 5–20 kDa proteins that sterically occlude key protein binding and active site motifs^{24,25}.
179 Breaking this rule, the 35 kDa anti-Gabija protein Gad1 is one of the largest described viral
180 protein–protein inhibitors of host immune signaling (Extended Data Fig. 4). Whereas most viral
181 evasion proteins >20 kDa in size are enzymatic domains that catalytically modify target host
182 factors or signaling molecules, the large size of Gad1 is necessary to bind, oligomerize, and

183 encircle around the entire host GajAB complex. Resistance to small phage proteins that simply
184 block the GajA active site may explain why Gabija is a highly prevalent defense system in diverse
185 bacterial phyla. Additionally, a key question opened by our structures of the Gabija complex is
186 how GajB helicase activity is linked to activation of the GajA nuclease domain to control DNA
187 target cleavage. Gad1 encasing the GajAB complex to trap it in an inactive state reveals a new
188 mechanism for evasion of host defense and provides a key template to understand how viruses
189 disrupt the complex mechanisms of activation of diverse anti-phage defense systems in bacteria.

190 **References**

- 191 1. Doron, S. *et al.* Systematic discovery of antiphage defense systems in the microbial
192 pangenome. *Science* **359**, eaar4120 (2018).
- 193 2. Gao, L. *et al.* Diverse enzymatic activities mediate antiviral immunity in prokaryotes. *Science*
194 **369**, 1077–1084 (2020).
- 195 3. Millman, A. *et al.* An expanded arsenal of immune systems that protect bacteria from phages.
196 *Cell Host Microbe* **30**, 1556-1569.e5 (2022).
- 197 4. Rousset, F. *et al.* Phages and their satellites encode hotspots of antiviral systems. *Cell Host*
198 *Microbe* **30**, 740-753.e5 (2022).
- 199 5. Vassallo, C. N., Doering, C. R., Littlehale, M. L., Teodoro, G. I. C. & Laub, M. T. A functional
200 selection reveals previously undetected anti-phage defence systems in the *E. coli*
201 pangenome. *Nat. Microbiol.* **7**, 1568–1579 (2022).
- 202 6. Tesson, F. *et al.* Systematic and quantitative view of the antiviral arsenal of prokaryotes. *Nat.*
203 *Commun.* **13**, 2561 (2022).
- 204 7. Payne, L. J. *et al.* PADLOC: a web server for the identification of antiviral defence systems in
205 microbial genomes. *Nucleic Acids Res.* **50**, W541–W550 (2022).
- 206 8. Hopfner, K.-P. Invited review: Architectures and mechanisms of ATP binding cassette
207 proteins. *Biopolymers* **105**, 492–504 (2016).
- 208 9. Aravind, L., Leipe, D. D. & Koonin, E. V. Toprim—a conserved catalytic domain in type IA and
209 II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. *Nucleic*
210 *Acids Res.* **26**, 4205–4213 (1998).
- 211 10. Berger, J. M., Gamblin, S. J., Harrison, S. C. & Wang, J. C. Structure and mechanism of
212 DNA topoisomerase II. *Nature* **379**, 225–232 (1996).
- 213 11. Schiltz, C. J., Lee, A., Partlow, E. A., Hosford, C. J. & Chappie, J. S. Structural
214 characterization of Class 2 OLD family nucleases supports a two-metal catalysis mechanism
215 for cleavage. *Nucleic Acids Res.* **47**, 9448–9463 (2019).

- 216 12. Schiltz, C. J., Adams, M. C. & Chappie, J. S. The full-length structure of *Thermus*
217 *scotoductus* OLD defines the ATP hydrolysis properties and catalytic mechanism of Class 1
218 OLD family nucleases. *Nucleic Acids Res.* **48**, 2762–2776 (2020).
- 219 13. Sironi, G. Mutants of *Escherichia coli* unable to be lysogenized by the temperate
220 bacteriophage P2. *Virology* **37**, 163–176 (1969).
- 221 14. Sironi, G., Bialy, H., Lozeron, H. A. & Calendar, R. Bacteriophage P2: Interaction with
222 phage lambda and with recombination-deficient bacteria. *Virology* **46**, 387–396 (1971).
- 223 15. Lindahl, G. On the control of transcription in bacteriophage P2. *Virology* **46**, 620–633
224 (1971).
- 225 16. Raney, K. D., Byrd, A. K. & Aarattuthodiyil, S. Structure and Mechanisms of SF1 DNA
226 Helicases. *Adv. Exp. Med. Biol.* **767**, 17–46 (2013).
- 227 17. Gorbalyena, A. E. & Koonin, E. V. Helicases: amino acid sequence comparisons and
228 structure-function relationships. *Curr. Opin. Struct. Biol.* **3**, 419–429 (1993).
- 229 18. Tanner, N. K. & Linder, P. DExD/H Box RNA Helicases: From Generic Motors to Specific
230 Dissociation Functions. *Mol. Cell* **8**, 251–262 (2001).
- 231 19. Korolev, S., Hsieh, J., Gauss, G. H., Lohman, T. M. & Waksman, G. Major Domain
232 Swiveling Revealed by the Crystal Structures of Complexes of *E. coli* Rep Helicase Bound to
233 Single-Stranded DNA and ADP. *Cell* **90**, 635–647 (1997).
- 234 20. Lee, J. Y. & Yang, W. UvrD Helicase Unwinds DNA One Base Pair at a Time by a Two-
235 Part Power Stroke. *Cell* **127**, 1349–1360 (2006).
- 236 21. Ordabayev, Y. A., Nguyen, B., Kozlov, A. G., Jia, H. & Lohman, T. M. UvrD helicase
237 activation by MutL involves rotation of its 2B subdomain. *Proc. Natl. Acad. Sci. U. S. A.* **116**,
238 16320–16325 (2019).
- 239 22. Cheng, R. *et al.* A nucleotide-sensing endonuclease from the Gabija bacterial defense
240 system. *Nucleic Acids Res.* **49**, 5216–5229 (2021).

- 241 23. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. & Davidson, A. R. Bacteriophage genes
242 that inactivate the CRISPR/Cas bacterial immune system. *Nature* **493**, 429–432 (2013).
- 243 24. Stanley, S. Y. & Maxwell, K. L. Phage-Encoded Anti-CRISPR Defenses. *Annu. Rev.*
244 *Genet.* **52**, 445–464 (2018).
- 245 25. Hampton, H. G., Watson, B. N. J. & Fineran, P. C. The arms race between bacteria and
246 their phage foes. *Nature* **577**, 327–336 (2020).
- 247 26. Hobbs, S. J. *et al.* Phage anti-CBASS and anti-Pycsar nucleases subvert bacterial
248 immunity. *Nature* **605**, 522–526 (2022).
- 249 27. Huiting, E. *et al.* Bacteriophages inhibit and evade cGAS-like immune function in
250 bacteria. *Cell* **0**, (2023).
- 251 28. Jenson, J. M., Li, T., Du, F., Ea, C.-K. & Chen, Z. J. Ubiquitin-like conjugation by
252 bacterial cGAS enhances anti-phage defence. *Nature* **616**, 326–331 (2023).
- 253 29. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
254 583–589 (2021).
- 255 30. Mirdita, M. *et al.* ColabFold: making protein folding accessible to all. *Nat. Methods* **19**,
256 679–682 (2022).
- 257 31. Lebbink, J. H. G. *et al.* Magnesium coordination controls the molecular switch function of
258 DNA mismatch repair protein MutS. *J. Biol. Chem.* **285**, 13131–13141 (2010).
- 259 32. Wang, J. Y., Pausch, P. & Doudna, J. A. Structural biology of CRISPR–Cas immunity
260 and genome editing enzymes. *Nat. Rev. Microbiol.* **20**, 641–656 (2022).
- 261 33. Morehouse, B. R. *et al.* Cryo-EM structure of an active bacterial TIR–STING filament
262 complex. *Nature* **608**, 803–807 (2022).
- 263 34. Hogrel, G. *et al.* Cyclic nucleotide-induced helical structure activates a TIR immune
264 effector. *Nature* **608**, 808–812 (2022).

- 265 35. Duncan-Lowey, B. *et al.* Cryo-EM structure of the RADAR supramolecular anti-phage
266 defense complex. 2022.08.17.504323 Preprint at <https://doi.org/10.1101/2022.08.17.504323>
267 (2022).
- 268 36. Gao, Y. *et al.* Molecular basis of RADAR anti-phage supramolecular assemblies. *Cell*
269 **186**, 999-1012.e20 (2023).
- 270 37. Kagan, J. C., Magupalli, V. G. & Wu, H. SMOCs: supramolecular organizing centres that
271 control innate immunity. *Nat. Rev. Immunol.* **14**, 821–826 (2014).
- 272 38. Ablasser, A. & Chen, Z. J. cGAS in action: Expanding roles in immunity and
273 inflammation. *Science* **363**, eaat8657 (2019).
- 274

275 **Figure Legends**

276 **Figure 1 | Structure of the Gabija anti-phage defense complex.**

277 **a**, Schematic of *B. cereus* Gabija defense operon and domain organization of GajA and GajB. **b**,
278 Overview of the GajAB X-ray crystal structure shown in three orientations. GajA protomers are
279 depicted in two shades of blue and GajB protomers are in red. **c**, Isolated GajA monomer (top)
280 and comparison with a *TsOLD* nuclease monomer (bottom) (Protein Data Bank (PDB) ID 6P74)¹².
281 **d**, Close-up view of GajA (left) and *BpOLD* (right) (PDB ID 6NK8)¹¹ Toprim catalytic residues.
282 Location of GajA cutaway image is indicated with a box in (c) and magnesium ions are depicted
283 as grey spheres. **e**, Isolated GajB monomer (top) and comparison with *EcUvrD* (bottom) (PDB ID
284 2IS2)²⁰. **f**, Close-up view of GajB (left) and *EcUvrD* (right) DEXQD-box motif. Location of GajB
285 cutaway image is indicated with a box in (e).

286

287 **Figure 2 | Mechanism of Gabija supramolecular complex assembly.**

288 **a**, Schematic model of GajAB complex formation by GajA tetramerization and GajB docking. **b**,
289 Overview of the GajA $\alpha 2^D$ – $\alpha 2^D$ dimerization interface and detailed view of interacting residues.
290 For clarity, each GajA monomer is depicted in two shades of blue. **c**, Overview of the GajA–GajA
291 ATPase interaction and detailed view of inter-subunit D135–R139 interaction. **d**, Overview of the
292 minimal GajB–GajB dimer interface and detailed view of GajB–GajB hydrophobic interactions
293 centered around Y119 and I122. **e**, Overview of the GajA–GajB interface highlighting proximity of
294 GajA ABC ATPase and GajB helicase active site residues (left) with box indicating location of
295 GajA R97 and GajB Q150 interaction (right). **f**, Analysis of GajA and GajB mutations in the GajA–
296 GajB (A–B), GajA–GajA (A–A), and GajB–GajB (B–B) multimerization interfaces on the ability of
297 the *B. cereus* Gabija operon to defend cells against phage infection. Data represent the phage
298 SP β average plaque-forming units (PFU) mL^{-1} of three biological replicates with individual data
299 points shown.

300

301 **Figure 3 | Structural basis of viral evasion of Gabija defense.**

302 **a**, Schematic model of GajAB–Gad1 co-complex formation and domain organization of phage
303 Phi3T Gad1. **b**, Cryo-EM density map of *BcGajAB* in complex with Phi3T Gad1 shown in three
304 different orientations. The map is colored by the model, with Gad1 monomers depicted in two
305 shades of green. **c**, Side-view of the complete Gad1 octameric complex and **d**, top-down view of
306 the Gad1 tetrameric interface with boxes highlighting close-up views in (e–h). **e,f**, Zoomed-in
307 views of major Gad1–GajA interface contacts including a Gad1 positively charged loop (e) and
308 hydrophobic interactions with GajA $\alpha 2^D$ (f). **g,h**, Zoomed-in views of major Gad1–Gad1
309 oligomerization interactions including disulfide bonds in the C-terminal shoulder domain (g) and
310 fist–fist domain contacts modeled by rigid-body placement of an AlphaFold2 fist domain structure
311 prediction into the cryo-EM map (h). **i**, Two distinct conformations of Gad1 observed in the GajAB–
312 Gad1 co-complex structure. Differences in Gad1 arm domain rotation are highlighted on the right.
313 **j**, Analysis of Gad1 mutations in the GajA–Gad1 and Gad1–Gad1 multimerization interfaces on
314 the ability Gad1 to enable evasion of Gabija defense. Data represent PFU mL⁻¹ of phage SP β
315 infecting cells expressing *BcGabija* and *Shewanella* sp. phage 1/4 Gad1, or negative control (NC)
316 cells expressing either plasmid empty vector. *Shewanella* sp. phage 1/4 Gad1 residues are
317 numbered according to the Phi3T Gad1 structure. Data are the average of three biological
318 replicates with individual data points shown.

319

320 **Figure 4 | Inhibition of Gabija DNA binding and cleavage enables viral evasion.**

321 **a**, Cartoon representation of the GajAB–Gad1 co-complex structure with modeled DNA based on
322 structural homology with *E. coli* MutS (PDB ID 3K0S)³¹. **b**, Isolated GajA protomer with modeled
323 DNA bound to the Toprim domain (top) and same GajA promoter with Gad1 demonstrating
324 significant steric clashes between Gad1 and the path of DNA (bottom). **c,d**, Biochemical analysis
325 of GajAB 56-bp target DNA binding (c) and target cleavage (d) demonstrates that Gad1 potently
326 inhibits GajAB activity. Data are representative of three independent experiments. **e**, Model of

327 Gabija anti-phage defense and mechanism of Gad1 immune evasion.

328

329 **Methods**

330 **Bacterial strains and phages**

331 *B. subtilis* BEST7003 was grown in MMB (LB supplemented with 0.1 mM MnCl₂ and 5 mM MgCl₂)
332 with or without 0.5% agar at 37°C or 30°C respectively. Whenever applicable, media were
333 supplemented with ampicillin (100 µg mL⁻¹), chloramphenicol (34 µg mL⁻¹), or kanamycin (50 µg
334 mL⁻¹) to ensure the maintenance of plasmids. *B. subtilis* phages phi3T (BGSCID 1L1) and SP3
335 (BGSCID 1L5) were obtained from the Bacillus Genetic Stock Center (BGSC). Prophages were
336 induced using Mitomycin C (Sigma, M0503).

337 Phage titer was determined using the small drop plaque assay method³⁹. 400 µL of
338 overnight culture of bacteria was mixed with 0.5% agar and 30 mL MMB and poured into a 10
339 cm² plate followed by incubation for 1 h at room temperature. In cases of bacteria expressing
340 Gad1 homolog and Gad1 mutations, 0.1–1mM IPTG was added to the medium. 10-fold serial
341 dilutions in MMB were performed for each of the tested phages and 10 µL drops were put on the
342 bacterial layer. After the drops had dried up, the plates were inverted and incubated at room
343 temperature overnight. Plaque forming units (PFUs) were determined by counting the derived
344 plaques after overnight incubation and lysate titer was determined by calculating PFU mL⁻¹. When
345 no individual plaques could not be identified, a faint lysis zone across the drop area was
346 considered to be 10 plaques. Efficiency of plating (EOP) was measured by comparing plaque
347 assay results on control bacteria and bacteria containing the defense system and/or a candidate
348 anti-defense gene.

349

350 **Plasmid Construction**

351 For protein purification and biochemistry, *B. cereus* VD045 *GajA* (IMG ID 2519684552) and *GajB*
352 (IMG ID 2519684553) genes were codon-optimized for expression in *E. coli* and synthesized as

353 gBlocks (Integrated DNA Technologies) and cloned into custom pET vectors with an N-terminal
354 6xHis-SUMO2 fusion tag (GajB alone) or a C-terminal 6xHis tag (GajA alone). GajA and GajB
355 proteins were co-expressed together using custom pET vector with an N-terminal 6xHis-SUMO2
356 or N-terminal 6xHis-SUMO2-5xGS tag on GajA and ribosome binding site between GajA and
357 GajB. Phi3T and *Shewanella* sp. phage 1/4 Gad1 (IMG ID 2708680195) gBlocks were cloned into
358 a custom pBAD vector containing a chloramphenicol resistance gene and IPTG-inducible
359 promoter. For Gad1 pull-down assays, *Shewanella* sp. phage 1/4 Gad1 was cloned with a
360 ribosome binding site after the GajB gene in the N-terminal 6xHis-SUMO2-5xGS GajAB plasmid.

361 For plaque assays, the DNA of Gad1 was amplified from phage phi3T genome using
362 KAPA HiFi HotStart ReadyMix (Roche cat # KK2601). Since Gad1 was toxic in *B. subtilis* cells
363 containing Gabija, *Shewanella* sp. phage 1/4 Gad1 was used and synthesized by Genscript. Gad1
364 and related homologs were cloned into the pSG-thrC-Phspank vector⁴⁰ and transformed to DH5α
365 competent cells. The cloned vector and the vector containing Gad1 substitution and truncation
366 mutants were subsequently transformed into *B. subtilis* BEST7003 cells containing Gabija
367 integrated into the amyE locus¹, resulting in cultures expressing both Gabija and a Gad1 homolog.
368 As a negative control, a transformant with an identical plasmid containing GFP instead of the anti-
369 defense gene, was used. Transformation in *B. subtilis* was performed using MC medium as
370 previously described¹. Sanger sequencing was then applied to verify the integrity of the inserts
371 and the mutations. The pSG1 plasmids containing point mutations in Gabija were constructed by
372 restriction-enzyme subcloning Gabija sequence into pGEM9Z, site-directed mutagenesis as
373 previously described⁴¹, Gibson back into pSG1, and transformed into *B. subtilis* BEST7003 cells.
374 Sanger sequencing of the mutations regions was then applied to verify the mutations in Gabija.
375

376 **Protein expression and purification**

377 Recombinant GajAB and GajAB–Gad1 complexes were purified from *E. coli* as previously
378 described⁴². Briefly, expression plasmids described above were transformed into BL21(DE3) or

379 BL21(DE3)-RIL cells (Agilent), plated on MDG media plates (1.5% Bacto agar, 0.5% glucose, 25
380 mM Na₂HPO₄, 25 mM KH₂PO₄, 50 mM NH₄Cl, 5 mM Na₂SO₄, 0.25% aspartic acid, 2–50 µM trace
381 metals, 100 µg mL⁻¹ ampicillin, 34 µg mL⁻¹ chloramphenicol) and grown overnight at 37°C. Five
382 colonies were used to inoculate 30 mL of MDG starter overnight cultures (37°C 230 rpm). 10 mL
383 of MDG starter cultures were then inoculated in 1 L M9ZB expression cultures (47.8 mM
384 Na₂HPO₄, 22 mM KH₂PO₄, 18.7 mM NH₄Cl, 85.6 mM NaCl, 1% Cas-Amino acids, 0.5% glycerol,
385 2 mM MgSO₄, 2–50 µM trace metals, 100 µg mL⁻¹ ampicillin, 34 µg mL⁻¹ chloramphenicol) and
386 induced with 0.5 mM IPTG after reaching an OD₆₀₀ of ≥1.5 (overnight, 16°C, 230 rpm).

387 After overnight induction, cells were pelleted by centrifugation, resuspended, and lysed by
388 sonication in 60 mL lysis buffer (20 mM HEPES pH 7.5, 400 mM NaCl, 10% glycerol, 20 mM
389 Imidazole, 1 mM DTT). Lysate was clarified by centrifugation, and supernatant was poured over
390 Ni-NTA resin (Qiagen). Resin was then washed with lysis buffer, lysis buffer supplemented to 1
391 M NaCl, lysis buffer again, and finally eluted with lysis buffer supplemented to 300 mM Imidazole.
392 Samples were then dialyzed overnight in 14 kDa MWCO dialysis tubing (Ward's Science) with
393 SUMO2-cleavage by hSENP2 as previously described^{29,30}. hSENP2 did not efficiently cleave N-
394 terminal 6xHis-SUMO2-GajAB and the complex was therefore purified with an additional 5xGS
395 linker. Proteins for crystallography and cryo-EM were dialyzed in dialysis buffer (20 mM HEPES-
396 KOH pH 7.5, 250 mM KCl, and 1 mM DTT), purified by size exclusion chromatography using a
397 16/600 Superdex 200 column (Cytiva) and stored in gel filtration buffer (20 mM HEPES-KOH pH
398 7.5, 20 mM KCl, and 1 mM TCEP-KOH). Proteins for biochemical assays were dialyzed in dialysis
399 buffer, purified by size exclusion chromatography using a 16/600 Superdex 200 column (Cytiva)
400 or 16/600 Sephadryl 300 column (Cytiva) and stored in gel filtration buffer with 10% glycerol.
401 Purified proteins were concentrated to >10 mg mL⁻¹ using a 30 kDa MWCO centrifugal filter
402 (Millipore Sigma), aliquoted, flash frozen in liquid nitrogen, and stored at -80°C.

403 For Gad1 pull-down assays, SUMO2-5xGS-GajA-GajB-Gad1 point mutant plasmids were
404 transformed and expressed in BL21(DE3)-RIL cells and subject to Ni-NTA column

405 chromatography. Proteins were dialyzed overnight along with SUMO2 cleavage with SENP2.
406 Gad1 pulldown was analyzed by SDS-PAGE and Coomassie Blue staining.

407

408 **Crystallization and X-ray structure determination**

409 Crystals were grown in hanging drop format using EasyXtal 15-well trays (NeXtal). Native GajAB
410 crystals were grown at 18°C in 2 μ L drops mixed 1:1 with purified protein (10 mg mL⁻¹, 20 mM
411 HEPES 250 mM KCl, and 1 mM TCEP-KOH) and reservoir solution (100 mM HEPES-NaOH pH
412 7.5, 2.4% PEG-400, and 2.2 M ammonium sulfate). Crystals were grown for 7 days before cryo-
413 protection with reservoir solution supplemented with 25% glycerol and harvested by plunging in
414 liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon Source (beamlines
415 24-ID-C and 24-ID-E). Data were processed using the SSRL autoxds script (A. Gonzalez,
416 Stanford SSRL). Experimental phase information was determined by molecular replacement
417 using monomeric GajA and GajB AlphaFold2 predicted structures^{29,30} in Phenix⁴³. Model building
418 was completed in Coot²² and then refined in Phenix. The final structure was refined to
419 stereochemistry statistics as reported in Extended Data Table 1. Structure images and figures
420 were prepared in PyMOL.

421

422 **Electrophoretic mobility shift assay**

423 56-bp sequence-specific motif dsDNA (5' TTTTTTTTTT TTTTTTTAAT AACCCGGTTA
424 TTTTTTTTTT TTTTTTTTTT 3')²² was incubated with a final concentration of 2, 5, or 10
425 μ M purified GajAB or GajAB–Gad1 complexes in 20 μ L gel shift reactions containing 1 μ M dsDNA,
426 5 mM CaCl₂, and 20 mM Tris-HCl pH 8.0 for 30 min at 4°C. 10 μ L was then mixed with 2 μ L of
427 50% glycerol and separated on a 2% TB (Tris-borate) agarose gel. The gel was then run at 250
428 V for 45 min, post-stained with TB containing 10 μ g mL⁻¹ ethidium bromide rocking at room
429 temperature, de-stained in TB buffer for 40 min, and imaged on ChemiDoc MP Imaging System.

430

431 **DNA cleavage assay**

432 The same 56-bp dsDNA as above was incubated with GajAB or GajAB–Gad1 complexes in a 20
433 μL DNA cleavage reaction buffer containing 1 μM dsDNA, 1 μM GajAB or GajAB–Gad1, 1 mM
434 MgCl_2 , 20 mM Tris-HCl pH 9.0 for 20 min at 37°C. Following incubation, reactions were stopped
435 with DNA loading buffer containing EDTA and 10 μL was analyzed on a 2% TB agarose gel, which
436 was run at 250V for 45 min. The gel was then post-stained rocking at room temperature with TB
437 buffer containing 10 $\mu\text{g mL}^{-1}$ ethidium bromide, de-stained in TB buffer alone for 40 min, and
438 imaged on a ChemiDoc MP Imaging System.

439

440 **Cryo-EM sample preparation and data collection**

441 For the SUMO2-GajAB–Gad1 co-complex sample, 3 μL of 1 mg mL^{-1} was vitrified using a Mark
442 IV Vitrobot (Thermofisher). Prior to sample vitrification, 2/1 Carbon Quantfoil™ grids were glow
443 discharged using an easiGlow™ (Pelco). Grids were then double-sided blotted for 9s, constant
444 force of 0, 100% relative humidity chamber at 4°C, and a 10 s wait time prior to liquid ethane
445 plunge and storage in liquid nitrogen.

446 GajAB–Gad1 co-complex cryo-EM grids were screened using a Talos Arctica microscope
447 (Thermofisher) operating at 200 kV and the final map was collected on a Titan Krios microscope
448 (ThermoFisher) operating at 300 kV. Both microscopes operated with a K3 direct electron detector
449 (Gatan). SerialEM software version 3.8.6 was used for all data collection. For final data collection
450 a total of 9,243 movies were taken at a pixel size of 0.3115 Å, a total dose of 41.1 $\text{e}^- / \text{\AA}^2$, dose
451 per frame of 0.63 $\text{e}^- / \text{\AA}^2$ at a defocus range of range of -0.8 to -1.9 μm .

452

453 **Cryo-EM data processing**

454 SBGrid Consortium provided data-processing software. Movies were imported into
455 cryoSPARC⁴⁵ for patch-based motion correction, patch-based CTF estimation, 2D and 3D particle
456 classification, and non-uniform refinement. cryoSPARC data processing is outlined in Extended

457 Data Figure 6. Briefly, after patch-based CTF estimation, five hundred micrographs were selected
458 and autopicked using Blob Picker, which resulted in 625,295 particles after extracting from
459 micrographs. 2D classifications were then used to generate 5 templates for Template Picker from
460 which 110,654 particles were picked from 500 micrographs. After three more rounds of 2D
461 classification 648,298 particles from all 9,243 micrographs were used in ab initios (K = 3), followed
462 by heterogenous refinement. The best class with 573,410 particles was then used to go back and
463 extract from all micrographs, which resulted in 570,485 particles that were used in non-uniform
464 refinement resulting in a 2.86 Å C1 symmetry and 2.73 Å C2 symmetry map, which was then used
465 for model building.

466

467 **Cryo-EM model building**

468 Model building was performed in Coot⁴⁴ by manually docking AlphaFold2 predicted structures^{29,30}
469 as starting models and then manually completing refinement and model correction. To model the
470 Gad1 fist domain, an AlphaFold2 model of the Gad1 arm–fist region was superimposed on the
471 cryo-EM density of the manually built shoulder–arm region and then fit into density in Coot⁴⁴. To
472 complete the model for the sparse GajB density, the X-ray GajB structure was superimposed on
473 the cryo-EM density. GajAB–Gad1 model was refined in Phenix⁴³, and the structure
474 stereochemistry statistics are reported in Extended Data Table 2. Figures were prepared in
475 PyMOL and UCSF ChimeraX⁴⁶.

476

477 **Statistics and reproducibility**

478 Experimental details regarding replicates are found within figure legends.

479

480 **Extended References**

- 481 39. Mazzocco, A., Waddell, T. E., Lingohr, E. & Johnson, R. P. Enumeration of
482 bacteriophages using the small drop plaque assay system. *Methods Mol. Biol. Clifton NJ* **501**,
483 81–85 (2009).
- 484 40. Leavitt, A. *et al.* Viruses inhibit TIR gcADPR signaling to overcome bacterial defense.
485 *Nature* 1–3 (2022) doi:10.1038/s41586-022-05375-9.
- 486 41. Liu, H. & Naismith, J. H. An efficient one-step site-directed deletion, insertion, single and
487 multiple-site plasmid mutagenesis protocol. *BMC Biotechnol.* **8**, 91 (2008).
- 488 42. Zhou, W. *et al.* Structure of the Human cGAS-DNA Complex Reveals Enhanced Control
489 of Immune Surveillance. *Cell* **174**, 300–311.e11 (2018).
- 490 43. Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons and
491 electrons: recent developments in Phenix. *Acta Crystallogr. Sect. Struct. Biol.* **75**, 861–877
492 (2019).
- 493 44. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta
494 Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 (2004).
- 495 45. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for
496 rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).
- 497 46. Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers,
498 educators, and developers. *Protein Sci. Publ. Protein Soc.* **30**, 70–82 (2021).
- 499 47. Yin, P., Zhang, Y., Yang, L. & Feng, Y. Non-canonical inhibition strategies and structural
500 basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems. *J. Mol. Biol.* **435**,
501 167996 (2023).
- 502 48. Tock, M. R. & Dryden, D. T. The biology of restriction and anti-restriction. *Curr. Opin.
503 Microbiol.* **8**, 466–472 (2005).
- 504 49. Wilkinson, M. *et al.* Structures of RecBCD in complex with phage-encoded inhibitor
505 proteins reveal distinctive strategies for evasion of a bacterial immunity hub. *eLife* **11**, e83409
506 (2022).

507 50. Athukoralage, J. S. *et al.* An anti-CRISPR viral ring nuclease subverts type III CRISPR
508 immunity. *Nature* **577**, 572–575 (2020).

509

510 **Acknowledgements** The authors are grateful to J. Asnes, J. Griffen, and members of the
511 Kranzusch lab and Sorek lab for helpful comments and discussion and A. Lu for assistance with
512 X-ray data collection. The work was funded by grants to P.J.K. from the Pew Biomedical Scholars
513 program, the Burroughs Wellcome Fund PATH program, The Mathers Foundation, The Mark
514 Foundation for Cancer Research, the Cancer Research Institute, the Parker Institute for Cancer
515 Immunotherapy, and the National Institutes of Health (1DP2GM146250-01) and grants to R.S.
516 from the European Research Council (ERC-AdG GA 101018520), the Israel Science Foundation
517 (MAPATS Grant 2720/22), the Ernest and Bonnie Beutler Research Program of Excellence in
518 Genomic Medicine, the Deutsche Forschungsgemeinschaft (SPP 2330, grant 464312965), and
519 the Knell Family Center for Microbiology. E.Y. is partially supported by the Israeli Council for
520 Higher Education (CHE) via the Weizmann Data Science Research Center. A.G.J. is supported
521 through a Life Science Research Foundation postdoctoral fellowship of the Open Philanthropy
522 Project. X-ray data were collected at the Northeastern Collaborative Access Team beamlines 24-
523 ID-C and 24-ID-E (P30 GM124165), and used a Pilatus detector (S10RR029205), an Eiger
524 detector (S10OD021527) and the Argonne National Laboratory Advanced Photon Source (DE-
525 AC02-06CH11357). Cryo-EM data were collected at the Harvard Cryo-EM Center for Structural
526 Biology at Harvard Medical School. We thank Theo Humphreys at PNCC for help with cryo-EM
527 data collection. A portion of this research was supported by NIH grant U24GM129547 and
528 performed at the PNCC at OHSU and accessed through EMSL (grid.436923.9), a DOE Office of
529 Science User Facility sponsored by the Office of Biological and Environmental Research.

530

531 **Author Contributions** The study was designed and conceived by S.P.A. and P.J.K. All protein
532 purification and biochemical assays were performed by S.P.A. and S.E.M. Crystallography

533 structural analysis was performed by S.P.A. Cryo-EM structural analysis was performed by
534 S.P.A., A.G.J., and M.L.M. Model building and analysis was performed by S.P.A. and P.J.K.
535 Bioinformatics and protein sequence analysis was performed by E.Y., A.L., G.A, and R.S. Phage
536 challenge assays were performed by A.L. and R.S. Figures were prepared by S.P.A. with
537 assistance from S.E.M. The manuscript was written by S.P.A. and P.J.K. All authors contributed
538 to editing the manuscript and support the conclusions.

539

540 **Competing Interests** R.S. is a scientific cofounder and advisor of BiomX and Ecophage. The
541 other authors declare no competing interests.

542

543 **Additional Information**

544 Correspondence and requests for materials should be addressed to P.J.K.

545

546 **Data Availability Statement**

547 Coordinates and structure factors of the Gabija GajAB complex have been deposited in PDB
548 under the accession code 8SM3. Coordinates and density maps of the GajAB–Gad1 co-complex
549 are being deposited with PDB and EMDB under accession codes NNNN and NNNN. All other
550 data are available in the manuscript or the supplementary materials.

551 **Extended Data Figure Legends**

552 **Extended Data Figure 1 | GajA and GajB form a supramolecular complex that cleaves**
553 **phage lambda DNA *in vitro*.**

554 **a**, Size-exclusion chromatography (16/600 S200) analysis of recombinant *BcGajA* and *BcGajB*
555 proteins, and the co-expressed *BcGajAB* complex. Brackets indicate fractions collected for
556 biochemical and structural analysis. **b**, SDS-PAGE analysis of purified GajA, GajB, and GajAB.
557 Asterisk indicates minor contamination with the *E. coli* protein ArnA. **c**, Agarose gel analysis of
558 the ability of GajA, GajB, and GajAB to cleave a 56-bp dsDNA demonstrates that GajA alone and
559 the GajAB complex can cleave target DNA. **d**, Structural comparison of GajB and *EcRep* (PDB
560 ID 1UAA)¹⁹ demonstrates the GajB 2B domain is rotated in a partially active intermediate position
561 in the GajAB complex structure.

562

563 **Extended Data Figure 2 | Structural characterization of GajA.**

564 **a**, Structure-guided alignment of GajA proteins from indicated bacteria colored according to amino
565 acid conservation. The determined *Bacillus cereus* VD045 GajA secondary structure is displayed,
566 and active-site and oligomerization interface residues are annotated according to the key below.
567 Secondary structure abbreviations include ABC ATPase domain (ABC), dimerization domain (D),
568 and Toprim domain (T).

569

570 **Extended Data Figure 3 | Structural characterization of GajB.**

571 **a**, Structure-guided alignment of GajB proteins from indicated bacteria colored according to amino
572 acid conservation. The determined *Bacillus cereus* VD045 GajB secondary structure is displayed,
573 and active-site and oligomerization interface residues are annotated according to the key below.

574

575 **Extended Data Figure 4 | Size comparison of Gad1 to known phage immune evasion**
576 **proteins.**

577 **a**, Analysis of known phage immune evasion proteins according to function and molecular weight
578 demonstrates that Gad1 is atypically large for an evasion protein that functions through protein–
579 protein interactions with a host anti-phage defense system. Phage immune evasion proteins are
580 categorized and exhibited as colored dots colored according to the key below. Notable evasion
581 proteins are indicated with text labels^{23–27,40,47–50}.

582

583 **Extended Data Figure 5 | Biochemical characterization of Gad1 requirements for binding**
584 **to the GajAB complex.**

585 **a**, Top, size-exclusion chromatography analysis (16/600 S200) of SUMO2-tagged *BcGajAB* with
586 or without phage Phi3T Gad1 used for cryo-EM structural studies. Bottom, size-exclusion
587 chromatography analysis (16/600 S300) of *BcGajAB* with or without *Shewanella* phage 1/4 Gad1
588 used for biochemical studies. *Shewanella* phage 1/4 Gad1 was used preferentially for biochemical
589 studies due to less toxicity during *E. coli* expression. **b**, SDS-PAGE analysis of purified SUMO2-
590 tagged GajAB, SUMO2-tagged GajAB in complex with phage Phi3T Gad1, untagged GajAB, and
591 untagged GajB in complex with *Shewanella* phage 1/4 Gad1. **c**, SDS-PAGE analysis of Ni-NTA
592 co-purified GajA, GajB, and GajAB with *Shewanella* phage 1/4 Gad1 indicates that Gad1 only
593 binds the fully assembled GajAB complex. Asterisk indicates minor contamination with the *E. coli*
594 protein ArnA.

595

596 **Extended Data Figure 6 | Cryo-EM data processing GajAB–Gad1 co-complex.**

597 **a**, Section of a representative electron micrograph (n = 9,243) of SUMO2–GajAB in complex with
598 phage Phi3T Gad1. Scale bar is 50 nm. **b**, Data processing scheme used to generate the final
599 2.73 Å map.

600

601 **Extended Data Figure 7 | GajAB–Gad1 co-complex Cryo-EM map quality and model to map**
602 **fitting.**

603 **a**, Reconstruction of the GajAB–Gad1 co-complex colored by local resolution. **b**, Fourier shell
604 correlation (FSC) of the EM map. **c**, GajA, GajB, and Gad1 map to model fit for designated
605 regions. **d,e,f**, Isolated GajA, GajB, Gad1 density maps with model fitting. **g**, GajAB–Gad1 model
606 that was used for refining the cryo-EM map for Extended Data Table 2. **h**, Left, sections of Gad1
607 chains that were built *de novo* from the cryo-EM density and built using rigid-body placement of
608 AlphaFold2 modeled residues. Right, cryo-EM density used to fit placement of Gad1 fist–fist
609 domain contacts that complete protomer interactions.

610

611 **Extended Data Figure 8 | Structural characterization of Gad1.**

612 **a**, Structure-guided alignment of Gad1 proteins from indicated phage or prophage genomes
613 colored according to amino acid conservation. The *Bacillus* phage Phi3T Gad1 secondary
614 structure is displayed according to the two different conformations observed in the GajAB–Gad1
615 co-complex structure. Oligomerization interface residues are annotated according to the key
616 below.

617

618 **Extended Data Figure 9 | Biochemical characterization of Gad1 mutants that disrupt GajAB
619 complex binding.**

620 **a**, SDS-PAGE analysis of the ability of *Shewanella* phage 1/4 Gad1 mutant proteins to interact
621 with the GajAB complex. *Shewanella* phage 1/4 Gad1 mutant proteins were co-expressed with
622 SUMO2-tagged GajAB (GajA-tagged) and co-purified by Ni-NTA pulldown. *Shewanella* sp. phage
623 1/4 Gad1 residues are numbered according to the Phi3T Gad1 structure. **b**, Agarose gel analysis
624 of the ability of GajAB–Gad1 mutant complexes to cleave target 56-bp dsDNA after a minute and
625 20 minute incubation.


626

627 **Extended Data Figure 10 | Modeling DNA-bound GajA.**

628 **a,b**, Isolated GajA protomer modeled with DNA bound to the Toprim domain shown with surface


629 electrostatic potential (a) and in cartoon format (b). DNA modeling was performed using structural
630 homology with the *E. coli* MutS–DNA complex (PDB ID 3K0S)³¹. **c**, Zoomed-in view of the GajA
631 Toprim active site with modeled DNA.

Figure 1. Structure of the Gabija anti-phage defense complex.




a, Schematic of *B. cereus* Gabija defense operon and domain organization of GajA and GajB. **b**, Overview of the GajAB X-ray crystal structure shown in three orientations. GajA protomers are depicted in two shades of blue and GajB protomers are in red. **c**, Isolated GajA monomer (top) and comparison with a *Ts*OLD nuclease monomer (bottom) (Protein Data Bank (PDB) ID 6P74)¹². **d**, Close-up view of GajA (left) and *Bp*OLD (right) (PDB ID 6NK8)¹¹ Toprim catalytic residues. Location of GajA cutaway image is indicated with a box in (c) and magnesium ions are depicted as grey spheres. **e**, Isolated GajB monomer (top) and comparison with *Ec*UvrD (bottom) (PDB ID 2IS2)²⁰. **f**, Close-up view of GajB (left) and *Ec*UvrD (right) DEXQD-box motif. Location of GajB cutaway image is indicated with a box in (e).

Figure 2. Mechanism of Gabija supramolecular complex assembly.




a, Schematic model of GajAB complex formation by GajA tetramerization and GajB docking. **b**, Overview of the GajA α 2D- α 2D dimerization interface and detailed view of interacting residues. For clarity, each GajA monomer is depicted in two shades of blue. **c**, Overview of the GajA-GajA ATPase interaction and detailed view of inter-subunit D135-R139 interaction. **d**, Overview of the minimal GajB-GajB dimer interface and detailed view of GajB-GajB hydrophobic interactions centered around Y119 and I122. **e**, Overview of the GajA-GajB interface highlighting proximity of GajA ABC ATPase and GajB helicase active site residues (left) with box indicating location of GajA R97 and GajB Q150 interaction (right). **f**, Analysis of GajA and GajB mutations in the GajA-GajB (A-B), GajA-GajA (A-A), and GajB-GajB (B-B) multimerization interfaces on the ability of the *B. cereus* Gabija operon to defend cells against phage infection. Data represent the phage SP8 average plaque-forming units (PFU) mL^{-1} of three biological replicates with individual data points shown.

Figure 3. Structural basis of viral evasion of Gabija defense.




a, Schematic model of GajAB–Gad1 co-complex formation and domain organization of phage Phi3T Gad1. **b**, Cryo-EM density map of *BcGajAB* in complex with Phi3T Gad1 shown in three different orientations. The map is colored by the model, with Gad1 monomers depicted in two shades of green. **c**, Side-view of the complete Gad1 octameric complex and **d**, top-down view of the Gad1 tetrameric interface with boxes highlighting close-up views in (e–h). **e,f**, Zoomed-in views of major Gad1–GajA interface contacts including a Gad1 positively charged loop (e) and hydrophobic interactions with GajA α 2D (f). **g,h**, Zoomed-in views of major Gad1–Gad1 oligomerization interactions including disulfide bonds in the C-terminal shoulder domain (g) and fist–fist domain contacts modeled by rigid-body placement of an AlphaFold2 fist domain structure prediction into the cryo-EM map (h). **i**, Two distinct conformations of Gad1 observed in the GajAB–Gad1 co-complex structure. Differences in Gad1 arm domain rotation are highlighted on the right. **j**, Analysis of Gad1 mutations in the GajA–Gad1 and Gad1–Gad1 multimerization interfaces on the ability Gad1 to enable evasion of Gabija defense. Data represent PFU mL⁻¹ of phage SP β infecting cells expressing *BcGabija* and *Shewanella* sp. phage 1/4 Gad1, or negative control (NC) cells expressing either plasmid empty vector. *Shewanella* sp. phage 1/4 Gad1 residues are numbered according to the Phi3T Gad1 structure. Data are the average of three biological replicates with individual data points shown.

Figure 4. Inhibition of Gabija DNA binding and cleavage enables viral evasion.



a, Cartoon representation of the GajAB–Gad1 co-complex structure with modeled DNA based on structural homology with *E. coli* MutS (PDB ID 3K0S)³¹. **b**, Isolated GajA protomer with modeled DNA bound to the Toprim domain (top) and same GajA promoter with Gad1 demonstrating significant steric clashes between Gad1 and the path of DNA (bottom). **c,d**, Biochemical analysis of GajAB 56-bp target DNA binding (c) and target cleavage (d) demonstrates that Gad1 potently inhibits GajAB activity. Data are representative of three independent experiments. **e**, Model of Gabija anti-phage defense and mechanism of Gad1 immune evasion.


Extended Data Figure 1. GajA and GajB form a supramolecular complex that cleaves phage lambda DNA in vitro.



a, Size-exclusion chromatography (16/600 S200) analysis of recombinant *BcGajA* and *BcGajB* proteins, and the co-expressed *BcGajAB* complex. Brackets indicate fractions collected for biochemical and structural analysis. **b**, SDS-PAGE analysis of purified GajA, GajB, and GajAB. Asterisk indicates minor contamination with the *E. coli* protein ArnA. **c**, Agarose gel analysis of the ability of GajA, GajB, and GajAB to cleave target DNA demonstrates that GajA alone and the GajAB complex can cleave target DNA. **d**, Structural comparison of GajB and *EcRep* (PDB ID 1UAA)¹⁹ demonstrates the GajB 2B domain is rotated in a partially active intermediate position in the GajAB complex structure.

Extended Data Figure 2. Structural characterization of GajA.


a



a, Structure-guided alignment of GajA proteins from indicated bacteria colored according to amino acid conservation. The determined *Bacillus cereus* VD045 GajA secondary structure is displayed, and active-site and oligomerization interface residues are annotated according to the key below. Secondary structure abbreviations include ABC ATPase domain (ABC), dimerization domain (D), and Toprim domain (T).


Extended Data Figure 3. Structural characterization of GajB.

a




a, Structure-guided alignment of GajB proteins from indicated bacteria colored according to amino acid conservation. The determined *Bacillus cereus* VD045 GajB secondary structure is displayed, and active-site and oligomerization interface residues are annotated according to the key below.

Extended Data Figure 4. Size comparison of Gad1 to known phage immune evasion proteins.




a, Analysis of known phage immune evasion proteins according to function and molecular weight demonstrates that Gad1 is atypically large for an evasion protein that functions through protein–protein interactions with a host anti-phage defense system. Phage immune evasion proteins are categorized and exhibited as colored dots colored according to the key below. Notable evasion proteins are indicated with text labels^{23–27,40,47–50}.

Extended Data Figure 5. Biochemical characterization of Gad1 requirements for binding to the GajAB complex.



a, Top, size-exclusion chromatography analysis (16/600 S200) of SUMO2-tagged *Bc*GajAB with or without phage Phi3T Gad1 used for cryo-EM structural studies. Bottom, size-exclusion chromatography analysis (16/600 S300) of *Bc*GajAB with or without *Shewanella* sp. phage 1/4 Gad1 used for biochemical studies. *Shewanella* sp. phage 1/4 Gad1 was used preferentially for biochemical studies due to less toxicity during *E. coli* expression. **b**, SDS-PAGE analysis of purified SUMO2-tagged GajAB, SUMO2-tagged GajAB in complex with phage Phi3T Gad1, untagged GajAB, and untagged GajB in complex with *Shewanella* sp. phage1/4 Gad1. **c**, SDS-PAGE analysis of Ni-NTA co-purified GajA, GajB, and GajAB with *Shewanella* sp. phage 1/4 Gad1 indicates that Gad1 only binds the fully assembled GajAB complex. Asterisk indicates minor contamination with the *E. coli* protein ArnA.


Extended Data Figure 6. Cryo-EM data processing GajAB–Gad1 co-complex.




a, Section of a representative electron micrograph ($n = 9,243$) of SUMO2–GajAB in complex with phage Phi3T Gad1. Scale bar is 50 nm. **b**, Data processing scheme used to generate the final 2.73 Å map.

Extended Data Figure 7. GajAB–Gad1 co-complex Cryo-EM map quality and model to map fitting.


a




b




c




d




e




f



g




h




a, Reconstruction of the GajAB–Gad1 co-complex colored by local resolution. **b**, Fourier shell correlation (FSC) of the EM map. **c**, GajA, GajB, and Gad1 map to model fit for designated regions. **d,e,f**, Isolated GajA, GajB, Gad1 density maps with model fitting. **g**, GajAB–Gad1 model that was used for refining the cryo-EM map for Extended Data Table 2. **h**, Left, sections of Gad1 chains that were built de novo from the cryo-EM density and built using rigid-body placement of AlphaFold2 modeled residues. Right, cryo-EM density used to fit placement of Gad1 fist–fist domain contacts that complete protomer interactions.

Extended Data Figure 8. Structural characterization of Gad1.




a, Structure-guided alignment of Gad1 proteins from indicated phage or prophage genomes colored according to amino acid conservation. The *Bacillus* phage Phi3T Gad1 secondary structure is displayed according to the two different conformations observed in the GajAB–Gad1 co-complex structure. Oligomerization interface residues are annotated according to the key below.

Extended Data Figure 9. Biochemical characterization of Gad1 mutants that disrupt GajAB complex binding.



a, SDS-PAGE analysis of the ability of *Shewanella* phage 1/4 Gad1 mutant proteins to interact with the GajAB complex. *Shewanella* phage 1/4 Gad1 mutant proteins were co-expressed with SUMO2-tagged GajAB (GajA-tagged) and co-purified by Ni-NTA pulldown. *Shewanella* sp. phage 1/4 Gad1 residues are numbered according to the Phi3T Gad1 structure. **b**, Agarose gel analysis of the ability of GajAB–Gad1 mutant complexes to cleave target 56-bp dsDNA after a minute and 20 minute incubation.

Extended Data Figure 10. Modeling DNA-bound GajA.



a,b, Isolated GajA protomer modeled with DNA bound to the Toprim domain shown with surface electrostatic potential (a) and in cartoon format (b). DNA modeling was performed using structural homology with the *E. coli* MutS–DNA complex (PDB ID 3K0S)³¹. **c**, Zoomed-in view of the GajA Toprim active site with modeled DNA.

Extended Data Table 1. Summary of X-ray data collection, phasing and refinement statistics

Gabija GajA–GajB (8SM3)	
Data collection	
Space group	P 6 ₂ 2 2
Cell dimensions	
a, b, c (Å)	215.79 215.79 173.81
α, β, γ (°)	90.0, 90.0, 120.0
Resolution (Å)	49.24–3.00 (3.10–3.00)
R_{pim}	4.0 (80.5)
$I / \sigma(I)$	15.4 (1.4)
Completeness (%)	100.0 (100.0)
Redundancy	18.1 (16.1)
Refinement	
Resolution (Å)	49.24–3.00
No. reflections	
Total	872109
Unique	48144
Free	2000
$R_{\text{work}} / R_{\text{free}}$	23.76 / 26.60
No. atoms	
Protein	8501
Ligand / ion	5
Water	–
B -factors	
Protein	130.62
Ligand / ion	175.63
Water	–
R.m.s. deviations	
Bond lengths (Å)	0.002
Bond angles (°)	0.441

*Data set was collected from an individual crystal. *Values in parentheses are for the highest resolution shell.

Extended Data Table 2. Cryo-EM data collection, refinement and validation statistics

GajAB-Gad1 co-complex (EMD-xxxx) (PDB xxxx)	
Data collection and processing	
Magnification	37,000
Voltage (kV)	300
Electron exposure (e ⁻ /Å ²)	41.1
Defocus range (μm)	-0.8 to -1.9
Pixel size (Å)	0.3115
Symmetry imposed	C2
Initial particle images (no.)	1,587,382
Final particle images (no.)	570,485
Map resolution (Å)	2.7
FSC threshold	0.143
Map resolution range (Å)	2.17–2.99
Refinement	
Initial model used (PDB code)	
Model resolution (Å)	2.71
FSC threshold	0.143
Model resolution range (Å)	2.71–2.73
Map sharpening B factor (Å ²)	-105.9
Model composition	
Non-hydrogen atoms	35,487
Protein residues	4,338
Ligands	0
B factors (Å ²)	
Proteins	38.34
R.m.s. deviations	
Bond lengths (Å)	0.003
Bond angles (°)	0.604
Validation	
MolProbity score	1.95
Clashscore	9.55
Poor rotamers (%)	3.35
Ramachandran plot	
Favored (%)	97.81
Allowed (%)	2.12
Disallowed (%)	0.07